Overview

Efficacy of 500µg Roflumilast Once Daily Versus Placebo Over 12 Weeks in Patients With Diabetes Mellitus Type 2. A Double Blind, Parallel Group, Proof of Concept Clinical Study

Status:
Completed
Trial end date:
2008-03-01
Target enrollment:
Participant gender:
Summary
This study is a proof of concept study to confirm in a standardized manner the therapeutic efficacy of roflumilast in type 2 diabetes mellitus patients.
Phase:
Phase 2
Details
Lead Sponsor:
AstraZeneca